New and Emerging drugs and device therapies for chronic heart failure in patients with systolic ventricular dysfunction

Canadian Journal of Cardiology

Volumn 27, Issue 3, 2011, Pages 296-301

  Rouleau, Jean L ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ALISKIREN; ALLOPURINOL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; IVABRADINE; LCZ 696; LEVOSIMENDAN; OMAPATRILAT; PROTEINASE INHIBITOR; RENIN INHIBITOR; ROLOFYLLINE; TOLVAPTAN; UNCLASSIFIED DRUG; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST; WARFARIN;

ACUTE HEART FAILURE; ANGIONEUROTIC EDEMA; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATION; DEFIBRILLATOR; DEVICE THERAPY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HEART RATE; HEART RATE VARIABILITY; HUMAN; LOW DRUG DOSE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; PHENOTYPE; PROGNOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 79960788388     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.02.010     Document Type: Review

References (44)

1. Heart Disease and Stroke Statistics. 2011 update. A report from the American Heart Association. Circulation 2011;123:e18-e209.
2. Ross H, Howlett J, Arnold JMO, et al. Treating the right patient at the right time: access to heart failure care. Can J Cardiol 2006;22:749-54.
3. Lee DS, Hohansen H, Gong Y, et al. Regional outcomes of heart failure in Canada. Can J Cardiol 2004;20:599-607.
4. White M, Rouleau JL. Overview of clinical trials in congestive heart failure. Can J Cardiol 1996;9:629-34.
5. Rouleau JL. The neurohumoral hypothesis and the treatment of heart failure. Can J Cardiol 1996;12:3F-8F.
6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-35.
7. Dimopoulos K, Salukhe TV, Coats AJ, et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol 2004;93:105-11.
8. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
9. Arnold JMO, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure, 2006: diagnosis and management. Can J Cardiol 2006;22:23-45.
10. Pitt B, Zannad F,RemmeWJ, et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
11. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
12. Li MJ, Huang CX, Okello E, et al. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can J Cardiol 2009;25:523-6.
13. Zannad F, McMurray JJ, Krum H, et al. the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;12:617-22.
14. Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the COPERNICUS study. J Am Coll Cardiol 2004; 43:1423-9.
15. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005; 26:2259-68.
16. Swedberg K, Komajda M, Böhm M, et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.
17. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001;142:393-401.
18. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007;297:1883-91.
19. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
20. Massie BM, O'Connor CM, Metra M, et al. PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-28.
21. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007; 297:1319-31.
22. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85:195-7.
23. Stanton EB, Hansen MS, Sole MJ, et al. PROFILE Investigators. Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. Can J Cardiol 2005;21:39-43.
24. Krum H, Massie B, Abraham WT, et al. on behalf of the ATMOSPHERE Investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: Rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-14.
25. The efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality of patients with chronic heart failure (PARADIGM-HF). ClinicalTrials. gov identifier: NCT01035255. Available at: http://clinicaltrials.gov/ct2/show/NCT01035255. Accessed April 18, 2011.
26. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 2002;106:920-6.
27. Using allopurinol to relieve symptoms in patients with heart failure and high uric acid levels (EXACT-HF). ClinicalTrials.gov identifier: NCT00987415. Available at: http://clinicaltrials.gov/ct2/show/NCT00987415. Accessed April 18, 2011.
28. Warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. ClinicalTrials.gov identifier: NCT00041938. Available at: http://clinicaltrials.gov/ct2/show/NCT00041938. Accessed April 18, 2011.
29. Tang AS, Ross H, Simpson CS, et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. Can J Cardiol 2005;21(suppl A):11A-8A.
30. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677-87.
31. Tang AS, Wells GA, Talajic M, et al. Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure.NEngl JMed2010;363:2385-95.
32. Nieuwlaat R, Eurlings LW, Cleland JG, et al. Atrial fibrillation and heart failure in cardiology practice: Reciprocal impact and combined management from the perspective of atrial fibrillation: Results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009; 53:1690-8.
33. Roy D, Talajic M, Nattel S, et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77.
34. Wilton SB, Fundytus, Ghali WA, et al. Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with and without left ventricular systolic dysfunction. Am J Cardiol 2010;106: 1284-91.
35. Patel MR, Dehmer GJ, Hirshfeld JW, et al. American College of Cardiology Foundation Appropriateness Criteria Task Force; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Thoracic Surgery; American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography; Heart Failure Society of America; Society of Cardiovascular Computed Tomography. CCF/SCAI/ STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2009;53:530-53.
36. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronaryartery bypass grafting versus stent implantation. N Engl J Med 2005;352: 2174-83.
37. Velazquez EJ, Lee KL, O'Connor CM, et al. The rationale and design of the surgical treatment for ischemic heart failure (STICH) trial. J Thorac Cardiovasc Surg 2007;134: 1540-7.
38. Brooks MM, Boden WE, Frye RL. Clinical implications of the BARI 2D and COURAGE trials: Overview. Coron Artery Dis 2010;21:383-5.
39. Howlett JG, Mann OE, Baillie R, et al. Heart failure clinics are associated with clinical benefit in both tertiary and community care settings: data from the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) registry. Can J Cardiol. 2009;25:e306-11.
40. Jones RH, Velazquez EJ, Michler RE, et al. STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009;360:1705-17.
41. Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: Best practice revolution. Eur Heart J 2010;16:1958-66.
42. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarkerguided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158:422-30.
43. Rector TS, Anand IS. Research needed to support clinical use of biomarkers as prognostic indicators for patients with heart failure. Cardiol Res Pract 2010. [Epub ahead of print]
44. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4.